Biomarker Development and Validation

Assay selection is based on the biological context of the biomarker, measurability, sample matrix, and operational feasibility. The HelixLab infrastructure supports an integrated multi-platform approach tailored to immunological, cellular, and molecular analytical needs.

• Immunological assays: methods such as Enzyme-Linked Immunosorbent Assay (ELISA), as protocol-defined.
• Cell-based assays: immune phenotyping and subpopulation analysis using flow cytometry, as protocol-defined.
• Genomic/molecular assays: biomarker support using project-appropriate platforms, as protocol-defined.
• Confirmatory assay strategies and methodological harmonization, when required.
• Analytical sensitivity and dynamic range, including Limit of Detection (LoD) and Limit of Quantification (LoQ).
• Assessment of whether clinically meaningful change lies within the analytical range.
• Measurement precision and variance structure, including intra-assay and inter-assay variability.
• Cross-platform comparability and bridging study requirements.

The reliability of biomarker data is directly dependent on the standardization of pre-analytical processes. Ensuring that samples are collected from the correct participant, at the correct time, and under appropriate conditions is essential, along with end-to-end traceability throughout transport, receipt, processing, and storage.

• Development of sampling guidelines, labeling standards, and site training programs.
• Protocol-defined acceptance and rejection criteria and deviation management.
• Sample tracking through a chain-of-custody approach.
• Biorepository integration for long-term storage and recall management, as protocol-defined.

Prior to implementation, the feasibility and operational sustainability of a biomarker measurement approach are evaluated. The objective is to identify an analytical workflow that meets protocol requirements while remaining robust and scalable.

• Assessment of matrix effects and potential interferences, including serum versus plasma differences.
• Evaluation of heterophilic antibodies and binding proteins.
• Definition of measurement range and target performance criteria, including minimal detectable change.
• Evaluation of signal-to-noise ratio in relation to biological relevance.
• Reagent and kit management, including lot-to-lot variability and change control scenarios.
• Operational capacity planning, including sample throughput, turnaround time (TAT), and interim analysis compatibility.

• • Analytical validation or verification activities assess performance parameters against predefined acceptance criteria. The objective is to ensure that the measurement is reproducible, traceable, and fit for the intended clinical research purpose.

    • Accuracy and precision assessments, including bias analysis and target coefficient of variation (CV%) levels.
    • Repeatability and reproducibility evaluations, accounting for operator, day, and instrument effects.
    • Specificity and selectivity assessments, including cross-reactivity and drug/metabolite interference.
    • Short- and long-term stability studies under defined transport and storage scenarios.
    • Quality Control (QC) strategy, including internal and external controls, trend and drift monitoring, and management of Out-of-Specification (OOS) and Out-of-Trend (OOT) results.

    documentation of study-specific gating strategies.

  • Standardization approaches to ensure operator-to-operator consistency.
  • Protocol-compliant result sets, including summary tables, population percentages or densities, and raw data outputs where required.
  • Data transfer compatible with sponsor and CRO systems, with format and frequency defined by protocol.

For biomarker outputs to be clinically interpretable, results must be reported in a manner that can be directly linked to protocol-defined endpoints. The interpretation framework is aligned with the statistical analysis plan and clinical requirements.

• Cut-off strategies and decision rules, as protocol-defined.
• Consideration of reference ranges and population characteristics.
• Standardized longitudinal assessment of within-subject changes.
• Reduction of site-to-site variability in multicenter studies through harmonization.

Integration of biomarker data into the clinical dataset requires timely and accurate data transfer. Reporting and data delivery are planned to align with sponsor and CRO systems.

• Definition of data formats and delivery frequency in accordance with the protocol.
• Compatibility with Electronic Data Capture (EDC) systems and electronic Case Report Forms (eCRFs), as protocol-defined.
• Query management and data clarification support.
• Timely and consistent data generation for studies requiring interim analyses.

All biomarker development and validation activities are conducted in compliance with clinical research regulations and data integrity principles. Auditability, traceability, and version control are fundamental.

• Compliance with ICH Good Clinical Practice (GCP) and audit-ready documentation practices.
• Alignment with ALCOA+ data integrity principles.
• Audit trail implementation and document version control.
• Quality approach aligned with ISO 15189 and ISO/IEC 17025 standards.